This bill makes additional technical changes, ensures coverage of biomarker precision tests whose efficacy is recognized by peer-reviewed studies, extends effective date.
Bill Provisions
Health insurance policy or Medicaid must cover biomarker precision medical testing.
Language added to law to specify precision medical testing be covered by a policy.
Applicable to every policy to guide treatment for insured's diagnosis and/or condition.
Removes requirement for covered person and prescribing practitioner to have access to clear, readily accessible and convenient process to request exception to coverage.
Removes language that biomarkers are not used to assess how a patient feels, functions, or survives; and language re types of biomarker, e.g., molecular, histologic.
Ensures coverage of biomarker precision medical tests whose efficacy, appropriateness are recognized by peer-reviewed literature and peer-reviewed scientific studies.
That are published in medical journals that meet nationally recognized requirements.
Extends effective date of Ch 754 of Laws of 2023, from Apr. 1, 2024 to Jan. 1, 2025.
Legislative History
On Jan. 4, 2024, bill introduced in Assembly; on Jan. 23, 2024, bill passed Assembly.
On Jan. 23, 2024, bill introduced in Senate; on Jan. 29, 2024, bill passed in Senate.
Effectiveness
Sections 1-4 effective with Ch. 754 2023 laws (S1196-A, A1673-A), on Jan. 1, 2025.
In effect Jan. 1, 2025 for policies/contracts issued or renewed on or after said date.
Feb. 2024 NY LEG Governor Approval
On Feb. 7, 2024, NY LEG governor approved bill A08502/S08040, signed as Ch. 29.
